Results 1 to 10 of about 10,352 (222)
Clinical and Translational Allergy, 2023 Background The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity ...
Roselie Achten
exaly +2 more sources
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
American Journal of Ophthalmology Case Reports, 2020 Purpose: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. Observations: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy.
Meghan Berkenstock +2 more
exaly +3 more sources
Cicatricial ectropion in a patient treated with dupilumab
American Journal of Ophthalmology Case Reports, 2017 Purpose: To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis. Observations: Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two ...
Julian Perry
exaly +3 more sources
Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis [PDF]
Dermatology and TherapySummary of the original article “Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis.” Dupilumab is a monoclonal antibody used to treat atopic dermatitis (AD) in patients 6 months and older.
Matthew P. Kosloski +16 more
doaj +2 more sources
Reactions Weekly, 2020 Ein neues Biologikum, das zur systemischen Behandlung der atopischen Dermatitis eingesetzt werden kann. Dupilumab ist bisher nicht direkt mit anderen systemischen Therapien verglichen worden und verursacht sehr häufig Augensymptome ...
+8 more sources
Clinical & Experimental Allergy, 2019 AbstractThe Th2 cytokines interleukin 4 (IL‐4) and IL‐13 and the heterodimeric IL‐4 receptor (IL‐4R) complexes that they interact with play a key role in the pathogenesis of allergic disorders. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL‐4 receptor alpha chain (IL‐4Rα), common to both IL‐4R complexes: type 1 (IL‐4Rα/γc; IL‐4 ...
Hani Harb, Talal A. Chatila
openaire +2 more sources
Dupilumab-associated cicatrizing ocular disease
American Journal of Ophthalmology Case Reports, 2022 Purpose: To describe three cases of bilateral cicatrizing conjunctivitis associated with dupilumab treatment for atopic dermatitis. Observations: Case 1 is a 69 year-old male with a history of mild, stable cicatrizing conjunctivitis thought to be ...
Amit K. Reddy +4 more
doaj +1 more source
Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.
PLoS ONE, 2022 BackgroundDupilumab is a human antibody that blocks the signaling of both interleukin-4 and interleukin-13 receptors. It has been approved for the treatment of moderate-to-severe atopic dermatitis.
Sunny Park +3 more
doaj +3 more sources
Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
Journal of Dermatological Treatment, 2023 Uveitis is a rare adverse event of dupilumab, that typically affects both eyes and often leads to discontinuation of therapy. In this article, we report a case of a 28-year-old female with atopic dermatitis who developed new-onset iridocyclitis, a form ...
Shiyu Zhang +8 more
doaj +1 more source
Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
Scientific Reports, 2021 Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have been accumulated, and it has been found that ocular surface diseases ...
Sunny Park +6 more
doaj +1 more source